Skip to content

Clinical Study on the Effectiveness of Arunveda Kondrion and Luxury High Power Kits for Treating Erectile Dysfunction

An Open-Label, Single-Centered Clinical Study Investigating the Efficacy of Combined Arunveda Kondrion Kit and Arunveda Luxury High Power Kit For Vasculogenic Erectile Dysfunction - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/10/075381
Enrollment
50
Registered
2024-10-16
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N529- Male erectile dysfunction, unspecified

Interventions

None listed

Sponsors

SUDHAKAR AYUR LAB INDIA PVT. LTD.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male subjects between the ages of 20 to 60 years. 2. Patients willing to participate and give informed consent. 3. Patients not having many complications or many secondary infections. 3. Participants with serum testosterone levels between 280 and 350 ng per dl Established diagnosis of erectile dysfunction (ED) for over 6 months and less than 5 years, had a baseline IIEF EF score between 11 and 25. 4. Those who were in a stable relationship for over 5. months with a minimum of 2 sexual attempts per month for at least 1 month prior to enrollment.

Exclusion criteria

Exclusion criteria: 1. Hypogonadism or anatomical deformity of the penis such as severe penile fibrosis. 2. History of significant pathological cardiovascular conditions such as congestive heart failure, lifethreatening arrhythmia or ischemic heart disease 3. Continuing history of alcohol and or drug abuse. 4. Subjects with neuromuscular disorders. 5. Subjects with secondary hypertension 6. Cases with severe diabetic complications such as cardiac disease, nephropathy, and foot ulcer. 7. Participation in other clinical trials. 8. Unwilling or unable to sign the informed consent.

Design outcomes

Primary

MeasureTime frame
1. To evaluate increase in blood flow, blood flow retention and visible veins on organ. 2. To evaluate blockage revival. 3. To evaluate the increase in Testosterone levels.Timepoint: Day 1, Day 10, Day 20, Day 30

Secondary

MeasureTime frame
1. To investigate the general immune functions 2. To evaluate changes in energy levels and libido. 3. To evaluate improvement in mood and stress levels.Timepoint: Day 1, Day 10, Day 20, Day 30

Countries

India

Contacts

Public ContactMs. Arpita Malgi

Samahitha Research Solutions

satyalm@samahitha.com9739001749

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026